OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone855-662-6732
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees33
Next Earnings Date9/20/2019 (Estimated)
OptionableNot Optionable
OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions
What is OncoSec Medical's stock symbol?
OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."
When did OncoSec Medical's stock split? How did OncoSec Medical's stock split work?
OncoSec Medical shares reverse split on the morning of Tuesday, May 21st 2019. The 1-10 reverse split was announced on Monday, May 20th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 20th 2019. An investor that had 100 shares of OncoSec Medical stock prior to the reverse split would have 10 shares after the split.
How were OncoSec Medical's earnings last quarter?
OncoSec Medical Inc (NASDAQ:ONCS) issued its earnings results on Wednesday, October, 25th. The biotechnology company reported ($2.80) earnings per share for the quarter, missing the consensus estimate of ($2.30) by $0.50. View OncoSec Medical's Earnings History.
When is OncoSec Medical's next earnings date?
What price target have analysts set for ONCS?
4 brokers have issued twelve-month price targets for OncoSec Medical's stock. Their predictions range from $6.00 to $40.00. On average, they anticipate OncoSec Medical's share price to reach $25.3333 in the next twelve months. This suggests a possible upside of 1,051.5% from the stock's current price. View Analyst Price Targets for OncoSec Medical.
What is the consensus analysts' recommendation for OncoSec Medical?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoSec Medical.
What are Wall Street analysts saying about OncoSec Medical stock?
Here are some recent quotes from research analysts about OncoSec Medical stock:
- 1. According to Zacks Investment Research, "OncoSec Medical Incorporated is a biomedical company engaged in the designing, development and commercialization of therapeutic oncology products. It also develops novel OMS ElectroOncology therapies and OncoSec Medical System for the treatment of solid tumors. OncoSec Medical Incorporated is based in San Diego, California. " (7/24/2019)
- 2. Maxim Group analysts commented, "OncoSec announced a collaboration agreement with Dana-Farber Cancer Institute whereby OncoSec acquired an exclusive option to licensing rights to CAR-T candidates and associated IP from research being conducted the Marasco Laboratory." (6/28/2019)
Has OncoSec Medical been receiving favorable news coverage?
News articles about ONCS stock have been trending negative on Friday, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. OncoSec Medical earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for OncoSec Medical.
Are investors shorting OncoSec Medical?
OncoSec Medical saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 240,300 shares, an increase of 42.4% from the July 31st total of 168,800 shares. Based on an average daily trading volume, of 154,200 shares, the days-to-cover ratio is presently 1.6 days. Currently, 4.5% of the company's shares are sold short. View OncoSec Medical's Current Options Chain.
Who are some of OncoSec Medical's key competitors?
Some companies that are related to OncoSec Medical include Iterum Therapeutics (ITRM), Trevena (TRVN), Tiziana Life Sciences (TLSA), Helix Biopharma (HBPCF), Ovid Therapeutics (OVID), Mersana Therapeutics (MRSN), vTv Therapeutics (VTVT), Entasis Therapeutics (ETTX), Neoleukin Therapeutics (NLTX), Checkpoint Therapeutics (CKPT), Trevi Therapeutics (TRVI), Synlogic (SYBX), Selecta Biosciences (SELB), Alpine Immune Sciences (ALPN) and Eyenovia (EYEN).
What other stocks do shareholders of OncoSec Medical own?
Who are OncoSec Medical's key executives?
OncoSec Medical's management team includes the folowing people:
- Dr. Avtar S. Dhillon, Co-Founder & Chairman (Age 57)
- Mr. Daniel J. O'Connor J.D., Pres, CEO & Director (Age 55)
- Mr. Punit S. Dhillon B.A., BA, Co-Founder & Director (Age 39)
- Ms. Sara M. Bonstein, CFO, COO & Company Sec. (Age 38)
- Dr. Christopher G. Twitty Ph.D., Chief Scientific Officer
Who are OncoSec Medical's major shareholders?
OncoSec Medical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (1.65%), Worth Venture Partners LLC (0.37%), BlackRock Inc. (0.31%), JPMorgan Chase & Co. (0.17%), Citadel Advisors LLC (0.12%) and Northern Trust Corp (0.11%). Company insiders that own OncoSec Medical stock include Alpha Holdings, Inc, Avtar S Dhillon, Daniel J O'connor, James M Demesa, Punit Dhillon and Richard B Slansky. View Institutional Ownership Trends for OncoSec Medical.
Which major investors are selling OncoSec Medical stock?
Which major investors are buying OncoSec Medical stock?
ONCS stock was purchased by a variety of institutional investors in the last quarter, including Worth Venture Partners LLC, JPMorgan Chase & Co., Citadel Advisors LLC and Private Advisor Group LLC. Company insiders that have bought OncoSec Medical stock in the last two years include Alpha Holdings, Inc, Daniel J O'connor, James M Demesa and Punit Dhillon. View Insider Buying and Selling for OncoSec Medical.
How do I buy shares of OncoSec Medical?
Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is OncoSec Medical's stock price today?
One share of ONCS stock can currently be purchased for approximately $2.20.
How big of a company is OncoSec Medical?
What is OncoSec Medical's official website?
How can I contact OncoSec Medical?
OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 855-662-6732 or via email at [email protected]
MarketBeat Community Rating for OncoSec Medical (NASDAQ ONCS)
MarketBeat's community ratings are surveys of what our community members think about OncoSec Medical and other stocks. Vote "Outperform" if you believe ONCS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCS will underperform the S&P 500 over the long term. You may vote once every thirty days.
